- ￥500 - 1800
- 齐源
- 100305
- 国产/进口
- 2025年07月10日
- FC
- 仓鼠
- 小鼠
7 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
CD3ε
- 级别：
CD3ε Antibody
- 目录编号：
CD3ε Antibody
- 克隆性：
单克隆
- 抗原来源：
仓鼠
- 保质期：
CD3ε Antibody
- 抗体英文名：
anti-mouse CD3ε Antibody-FITC
- 抗体名：
CD3ε Antibody
- 标记物：
FITC
- 宿主：
仓鼠
- 适应物种：
小鼠
- 免疫原：
CD3ε Antibody
- 亚型：
CD3ε Antibody
- 形态：
CD3ε Antibody
- 应用范围：
FC
- 保存条件：
2-8℃
- 浓度：
0.5 mg/ml
- 规格：
50 µg/500 µg
| 规格： | 50 µg | 产品价格： | ￥500.0 |
|---|---|---|---|
| 规格： | 500 µg | 产品价格： | ￥1800.0 |
anti-mouse CD3ε Antibody-FITC详细如下：
Description ：CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Igsuperfamily and primarily expressed on T cells, NK-T cells, and at different levels onthymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with theCD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCRsignal transduction, T cell activation, and antigen recognition by binding the peptide/MHCantigen complex.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Armenian Hamster
Immunogen ：H-2K -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with FITC under optimalconditions.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Excitation Laser ：Blue Laser (488 nm)
Description ：CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Igsuperfamily and primarily expressed on T cells, NK-T cells, and at different levels onthymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with theCD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCRsignal transduction, T cell activation, and antigen recognition by binding the peptide/MHCantigen complex.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Armenian Hamster
Immunogen ：H-2K -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with FITC under optimalconditions.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Excitation Laser ：Blue Laser (488 nm)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations：
1. Chei S, et al. 2020. Front Nutr. 7:583186. PubMed
2. Bertrand F, et al. 2017. Nat Commun. 8:2256. PubMed
3. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
4. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
5. Tomida S, et al. 2019. Sci Rep. 9:10751. PubMed
6. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
7. Schulteis R, et al. 2008. Blood. 112:4905. PubMed
8. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
9. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
10. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
11. Fornari T, et al. 2015. PLoS One. 10: 0142688. PubMed
12. Koning B, et al. 2006. Int Immunol. 1.403472222. PubMed
1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations：
1. Chei S, et al. 2020. Front Nutr. 7:583186. PubMed
2. Bertrand F, et al. 2017. Nat Commun. 8:2256. PubMed
3. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
4. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
5. Tomida S, et al. 2019. Sci Rep. 9:10751. PubMed
6. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
7. Schulteis R, et al. 2008. Blood. 112:4905. PubMed
8. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
9. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
10. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
11. Fornari T, et al. 2015. PLoS One. 10: 0142688. PubMed
12. Koning B, et al. 2006. Int Immunol. 1.403472222. PubMed
相关实验
当FITC在碱性溶液中与抗体蛋白反应时，主要是蛋白质上赖氨酸的r氨基与荧光素的硫碳胺键(thiocarbmide)结合，形成FITC-蛋白质结合物，即荧光抗体或荧光结合物。一个IgG分子中有86个赖氨酸残基，一般最多能结合15～20个，一个IgG分子可结合2～8个分子的FITC，其反应式如下FITC-N=C=S + N-H2-蛋白质 → FITC-NS-C-N-H2-蛋白质常用Marsshall(1958)法标记荧光抗体，也可以根据条件采用Chadwick等标记法或Clark
抗体二抗上连接有荧光染料。直接标记染色背景低，实验程序少尽量减少实验工序和过程，以保证实验的真实和准确性。因此在条件允许的范围内，建议尽量用直接标记的抗体进行实验。 3、流式抗体荧光标记的选择： 如果实验中检测单一指标：不同荧光标记在不同的仪器上强度不同。以某仪器为例：PE ＞APC ＞PE-Cy5 ＞PerCP ＞FITC ＞PerCP-Cy5.5，通常来说，PE最强，适用于弱表达抗原。FITC强度较弱，适用于强表达抗原，使用范围比较广。用户需根据检测的目标蛋白进行具体选择。 如果同时检测多个
ml三蒸水中即成； 方法与步骤： 根据Marshall氏法高效价的抗人球蛋白兔免疫血清，分离球蛋白。 1. 用0.15 mol/L NaCl的盐水及0.15 mol/L pH9.0的NaHCO3-Na2CO3缓冲液稀释使每毫升内含抗体10mg，缓冲液为总量的10%； 2. 将以上溶液降温至4℃，按蛋白：荧光素=50—80mg：1mg的比例加入异硫氰酸荧光素，在0—4℃下电磁搅拌12—14h； 3.用半饱和硫酸铵将标记球蛋白
文献支持
抗小鼠 CD3ε 荧光标记FITC 抗体
￥500 - 1800
